Alternative solution for menstrual cycle normalization in polycystic ovary syndrome


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective: To study the effectiveness of using a vitamin-mineral complex (VMC) based on myoinositol (MI) and D-chiroinositol (DCI) in a ratio of 5:1 to normalize the rhythm of menstruation and to restore ovulation. Materials and methods: Examinations were made in 268 women aged 18 to 39years (mean age 25.1 (5.3) years) with anovulatory polycystic ovary syndrome (PCOS) phenotypes and a normal body mass index. Phenotype A was detected in 126/268 (47%) women, phenotype B was found in 94/268 (35%), and phenotype D was identified in 48/268 (18%). All the patients included in the study were recommended a VMC based on MI and DCI in a ratio of 5:1 as one sachet taken twice a day for 3 months. Results: At 3 months after initiation of non-hormonal correction of the menstrual cycle, the restored menstruation rhythm was recorded in 174/268 (64.9%) patients within 24-38 days with a variability of no more than 7 days. Restoration of ovulation was observed in a significant proportion (146/268 (54.5%)) of patients (95% CI [43.4%; 65.7%]) who had taken for three months a VMC based on MI/DCI in a ratio of 5:1, manganese and folic acid (Dikirogen). At the same time, spontaneous ovulation was recorded in 67(25%) and 100 (37.3%) patients after one and two months, respectively. The side and undesirable effects, such as nausea and diarrheas, were noted in 1 (0.37%) and 2 (0.74%) patients, respectively. Conclusion: The use of the VMC based on MI/DCI in a ratio of 5:1 contributed to the normalization of the rhythm of menstruation and to the restoration of ovulation in most women with PCOS who well tolerated the complex.

Full Text

Restricted Access

About the authors

Nyurzhanna H. Khadzhieva

RZhD-Meditsina Central Clinical Hospital

Email: nurzhanna@yandex.ru
PhD, obstetrician-gynecologist

References

  1. Министерство здравоохранения РФ. Клинические рекомендации «Синдром поликистозных яичников». 2021.
  2. Teede H.J., Misso M.L., Costello M.F., Dokras A., Laven J., Moran L. et al. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil. Steril. 2018; 110(3): 364-79. https://dx.doi.org/10.1016/j.fertnstert.2018.05.004.
  3. American College of Obstetricians and Gynecologists’ Committee. ACOG Practice Bulletin No. 194: Polycystic Ovary Syndrome. Obstet. Gynecol. 2018; 131(6): e157-e171. https://dx.doi.org/10.1097/AOG.0000000000002656. Erratum in: ACOG Practice Bulletin No. 194: Polycystic Ovary Syndrome: Correction. Obstet. Gynecol. 2020; 136(3): 638. https://dx.doi.org/10.1097/AOG.0000000000004069.
  4. Chen Y., Fang S.Y. Potential genetic polymorphisms predicting polycystic ovary syndrome. Endocr. Connect. 2018; 7(5): R187-95. https://dx.doi.org/10.1530/EC-18-0121.
  5. Papadakis G., Kandaraki E.A., Garidou A., Koutsaki M., Papalou 0., Diamanti-Kandarakis E. et al. Tailoring treatment for PCOS phenotypes. Expert Rev. Endocrinol. Metab. 2021; 16(1): 9-18. https://dx.doi.org/10.1080/17446651.2021.1865152.
  6. Bevilacqua A., Bizzarri M. Inositols in insulin signaling and glucose metabolism. Int. J. Endocrinol. 2018; 25: 1968450. https://dx.doi.org/10.1155/2018/1968450.
  7. Ijuin T., Takenawa T. Regulation of insulin signaling and glucose transporter 4 (GLUT4) exocytosis by phosphatidylinositol 3,4,5-trisphosphate (PIP3) phosphatase, skeletal muscle, and kidney enriched inositol polyphosphate phosphatase (SKIP). J. Biol. Chem. 2012; 287(10): 6991-9. https://dx.doi.org/10.1074/jbc.M111.335539.
  8. Kim J.N., Han S.N., Kim H.K. Phytic acid and myo-inositol support adipocyte differentiation and improve insulin sensitivity in 3T3-L1 cells. Nutr. Res. 2014; 34(8): 723-31. https://dx.doi.org/10.1016/j.nutres.2014.07.015.
  9. Пустотина О.А. Применение инозитолов при синдроме поликистозных яичников. Эффективная фармакотерапия. 2020; 16(28): 24-34. [Pustotina O.A. Use of inositols in polycystic ovary syndrome. Effective pharmacotherapy. 2020; 16(28): 24-34.)]. https://dx.doi.org/10.33978/2307-3586-2020-16-28-24-34.
  10. Пустотина О.А., Дикке Г.Б., Остроменский В.В. Роль инозитола в репродукции человека. Акушерство и гинекология. 2022; 2: 111-8. [Pustotina O.A., Dikke G.B., Ostromensky V.V. The role of inositol in human reproduction. Obstetrics and Gynecology. 2022; 2: 111-8. (in Russian)]. https://dx.doi.org/10.18565/aig.2022.2.111-118.
  11. Громова О.А., Торшин И.Ю., Уварова Е.В., Тапильская Н.Г., Калачева А.Г. Систематический анализ биологических ролей и фармакологических свойств D-хироинозитола. Гинекология. 2020; 22(3): 21-8. https://dx.doi.org/10.26442/20795696.2020.3.200210.
  12. Gambioli R., Montanino O.M., Nordio M., Chiefari A., Puliani G., Unfer V. New insights into the activities of D-Chiro-Inositol: A narrative review. Biomedicines. 2021; 9(10): 1378. https://dx.doi.org/10.3390/biomedicines9101378.
  13. Gaspers L.D., Pierobon N., Thomas A.P. Intercellular calcium waves integrate hormonal control of glucose output in the intact liver. J. Physiol. 2019; 597(11): 2867-85. https://dx.doi.org/10.1113/JP277650.
  14. Di Segni C., Silvestrini A., Fato R., Bergamini C., Guidi F., Raimondo S. et al. Plasmatic and intracellular markers of oxidative stress in normal weight and obese patients with polycystic ovary syndrome. Exp. Clin. Endocrinol. Diabetes. 2017; 125(8): 506-13. https://dx.doi.org/10.1055/s-0043-111241.
  15. Даренская М.А., Колесников С.И., Гребенкина Л.А., Данусевич И.Н., Лазарева Л.М., Наделяева Я.Г., Даржаев З.Ю., Никитина О.А., Базарова Т.А., Колесникова Л.И. Анализ прои антиоксидантной активности крови у женщин с различными фенотипами синдрома поликистозных яичников и бесплодием. Акушерство и гинекология. 2017; 8: 86-91. https://dx.doi.org/10.18565/aig.2017.8.86-91.
  16. Genazzani A.D. Inositol as putative integrative treatment for PCOS. Reprod. Biomed. Online. 2016; 33(6): 770-80. https://dx.doi.org/10.1016/j.rbmo.2016.08.024.
  17. Pundir J., Psaroudakis D., Savnur P., Bhide P., Sabatini L., Teede H. et al. Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. BJOG. 2018; 125(3): 299-308. https://dx.doi.org/10.1111/1471-0528.14754.
  18. Iervolino M., Lepore E., Forte G., Lagana A.S., Buzzaccarini G., Unfer V. Natural molecules in the management of polycystic ovary syndrome (PCOS): An analytical review. Nutrients. 2021; 13(5): 1677. https://dx.doi.org/10.3390/nu13051677.
  19. Facchinettia F., Appetecchia M., Aragona C., Bevilacqua A., Bezerra Espinola M.S., Bizzarri M. et al. Experts opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond. Expert Opin. Drug Metab. Toxicol. 2020; 16(3): 255-74. https://dx.doi.org/10.1080/17425255.2020.1737675.
  20. Сапрыкина Л.В., Гульшин В.А. Возможности контроля овуляции у пациенток с синдромом поликистозных яичников на фоне терапии. РМЖ. 2018; 5(1): 29-32.
  21. ГОСТ Р. ИСО 5479-2002. Проверка отклонения распределения вероятностей от нормального распределения: Национальный стандарт Российской Федерации. М.; 2002. 31с. (Статистические методы).
  22. Nordio M., Basciani S., Camajani E. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. Eur. Rev. Med. Pharmacol. Sci. 2019; 23(12): 5512-21. https://dx.doi.org/10.26355/eurrev_201906_18223.
  23. Kalra B., Kalra S., Sharm a J.B. The inositols and polycystic ovary syndrome. Indian J. Endocrinol. Metab. 2016; 20(5): 720-4. https://dx.doi.org/10.4103/2230-8210.189231.
  24. Об оскалов а Т. А., Воронцова А. В., Звычайный М. А., Гущина Г. К., Майтесян М.М. Результаты применения комбинации миоинозитола и D-хироинозитола в соотношении 5:1 у женщин с синдромом поликистозных яичников. Гинекология. 2020; 22(6): 84-9. https://dx.doi.org/10.26442/20795696.2020.6.200548.
  25. Januszewski M., Issat T., Jakimiuk A.A., Santor-Zaczynska M., Jakimiuk A.J. Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS). Ginekol. Pol. 2019; 90(1): 7-10. https://dx.doi.org/10.5603/GP.2019.0002.
  26. Mendoza N., Diaz-Ropero M.P., Aragon M., Maldonado V., Llaneza P., Lorente J. et al. Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol. Endocrinol. 2019; 35(8): 695-700. https://dx.doi.org/10.1080/09513590.2019.1576620.
  27. Mendoza N., Galan M.I., Molina C., Mendoza-Tesarik R., Conde C., Mazheika M. et al. High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol. Endocrinol. 2020; 36(5): 398-401. https://dx.doi.org/10.1080/09513590.2019.1681959.
  28. Malvasi A., Casciaro F., Minervini M., Kosmas I., Mynbaev O.A., Pacella E. et al. Myoinositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. Eur. Rev. Med. Pharmacol. Sci. 2014; 18(2): 270-4.
  29. Громова О.А., Андреева Е.Н., Торшин И.Ю., Тапильская Н.Г., Уварова Е.В. Системно-биологический анализ ролей марганца в акушерстве и гинекологии: репродуктивное здоровье женщины, регуляция мен струального цикла и профилактика пороков развития плода. Вопросы гинекологии, акушерства и перинатологии. 2020; 19(1): 103-13. https://dx.doi.org/10.20953/1726-1678-2020-1-103-113.
  30. Chang H., Xie L., Ge H., Qi W., Yan W., Duojia Z. et al. Effects of hyperhomocysteinaemia and metabolic syndrome on reproduction in women with polycystic ovary syndrome: a secondary analysis. Reprod. Biomed. Online. 2019; 38(6): 990-8. https://dx.doi.org/10.1016/j.rbmo.2018.12.046.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies